Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2012

Open Access 01-04-2012 | Research article

Functional role of IL-22 in psoriatic arthritis

Authors: Anupam Mitra, Smriti K Raychaudhuri, Siba P Raychaudhuri

Published in: Arthritis Research & Therapy | Issue 2/2012

Login to get access

Abstract

Introduction

Interleukin-22 (IL-22) is a cytokine of IL-10 family with significant proliferative effect on different cell lines. Immunopathological role of IL-22 has been studied in rheumatoid arthritis (RA) and psoriasis. Here we are reporting the functional role of IL-22 in the inflammatory and proliferative cascades of psoriatic arthritis (PsA).

Method

From peripheral blood and synovial fluid (SF) of PsA (n = 15), RA (n = 15) and osteoarthritis (OA, n = 15) patients, mononuclear cells were obtained and magnetically sorted for CD3+ T cells. Fibroblast like synoviocytes (FLS) were isolated from the synovial tissue of PsA (n = 5), RA (n = 5) and OA (n = 5) patients. IL-22 levels in SF and serum were measured by enzyme linked immunosorbent assay (ELISA). Proliferative effect of human recombinant IL-22 (rIL-22) on FLS was assessed by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a yellow tetrazole) and CFSE dilution (Carboxyfluorescein succinimidyl ester) assays. Expression of IL-22Rα1 in FLS was determined by western blot.

Results

IL-22 levels were significantly elevated in SF of PsA patients (17.75 ± 3.46 pg/ml) compared to SF of OA (5.03 ± 0.39 pg/ml), p < 0.001. In MTT and CFSE dilution assays, rIL-22 (MTT, OD: 1.27 ± 0.06) induced significant proliferation of FLS derived from PsA patients compared to media (OD: 0.53 ± 0.02), p < 0.001. In addition, rIL-22 induced significantly more proliferation of FLS in presence of TNF-α. IL-22Rα1 was expressed in FLS of PsA, RA and OA patients. Anti IL-22R antibody significantly inhibited the proliferative effect of rIL-22. Further we demonstrated that activated synovial T cells of PsA and RA patients produced significantly more IL-22 than those of OA patients.

Conclusion

SF of PsA patients have higher concentration of IL-22 and rIL-22 induced marked proliferation of PsA derived FLS. Moreover combination of rIL-22 and TNF-α showed significantly more proliferative effect on FLS. IL-22Rα1 was expressed in FLS. Successful inhibition of IL-22 induced FLS proliferation by anti IL-22R antibody suggests that blocking of IL-22/IL-22R interaction may be considered as a novel therapeutic target for PsA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wright V, Moll JMH: Psoriatic arthritis. Seronegative Polyarthritis. Edited by: Wright V, Moll JMH. 1976, Amsterdam: North Holland Publishing Co, 169-223. Wright V, Moll JMH: Psoriatic arthritis. Seronegative Polyarthritis. Edited by: Wright V, Moll JMH. 1976, Amsterdam: North Holland Publishing Co, 169-223.
2.
go back to reference Gladman DD, Antoni C, Mease P, Clegg DO, Nash P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005, 64: ii14-17. 10.1136/ard.2004.032482.PubMedCentral Gladman DD, Antoni C, Mease P, Clegg DO, Nash P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005, 64: ii14-17. 10.1136/ard.2004.032482.PubMedCentral
3.
go back to reference Rahman P, Elder JT: Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005, 64: ii37-39. 10.1136/ard.2004.030775.PubMedCentral Rahman P, Elder JT: Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005, 64: ii37-39. 10.1136/ard.2004.030775.PubMedCentral
4.
go back to reference Gladman DD: Psoriatic arthritis. Dermatol Ther. 2004, 17: 350-363. 10.1111/j.1396-0296.2004.04038.x.CrossRef Gladman DD: Psoriatic arthritis. Dermatol Ther. 2004, 17: 350-363. 10.1111/j.1396-0296.2004.04038.x.CrossRef
5.
go back to reference Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O: Reduced synovial membrane macrophage numbers, ELAM1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993, 36: 893-900. 10.1002/art.1780360705.CrossRef Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O: Reduced synovial membrane macrophage numbers, ELAM1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993, 36: 893-900. 10.1002/art.1780360705.CrossRef
6.
go back to reference Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998, 25: 1544-1552. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998, 25: 1544-1552.
7.
go back to reference Raychaudhuri SP, Raychaudhuri SK, Genovese MC: IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012, 359: 419-429. 10.1007/s11010-011-1036-6.CrossRef Raychaudhuri SP, Raychaudhuri SK, Genovese MC: IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012, 359: 419-429. 10.1007/s11010-011-1036-6.CrossRef
8.
go back to reference Veale DJ, Ritchlin C, FitzGerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005, 64: ii26-29. 10.1136/ard.2004.031740.PubMedCentralCrossRef Veale DJ, Ritchlin C, FitzGerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005, 64: ii26-29. 10.1136/ard.2004.031740.PubMedCentralCrossRef
9.
go back to reference Espinoza LR, Espinoza CG, Cuéllar ML, Scopelitis E, Silveira LH, Grotendorst GR: Fibroblast function in psoriatic arthritis. II: increased expression of PDGF receptors and increased production of GF and cytokines. J Rheumatol. 1994, 21: 1507-1511. Espinoza LR, Espinoza CG, Cuéllar ML, Scopelitis E, Silveira LH, Grotendorst GR: Fibroblast function in psoriatic arthritis. II: increased expression of PDGF receptors and increased production of GF and cytokines. J Rheumatol. 1994, 21: 1507-1511.
10.
go back to reference van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP: Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006, 65: 1551-1557. 10.1136/ard.2005.050963.PubMedCentralCrossRef van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP: Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006, 65: 1551-1557. 10.1136/ard.2005.050963.PubMedCentralCrossRef
11.
go back to reference Gitter BD, Labus JM, Lees SL, Scheetz ME: Characteristics of human synovial fibroblast activation by IL-1β and TNF-α. Immunology. 1989, 66: 196-200.PubMedCentral Gitter BD, Labus JM, Lees SL, Scheetz ME: Characteristics of human synovial fibroblast activation by IL-1β and TNF-α. Immunology. 1989, 66: 196-200.PubMedCentral
12.
go back to reference Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T: Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2006, 33: 463-471. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T: Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2006, 33: 463-471.
13.
go back to reference Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001, 344: 907-9 16. 10.1056/NEJM200103223441207.CrossRef Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001, 344: 907-9 16. 10.1056/NEJM200103223441207.CrossRef
14.
go back to reference Ritchlin CT: Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists. Best Pract Res Clin Rheumatol. 2010, 24: 683-692. 10.1016/j.berh.2010.06.002.CrossRef Ritchlin CT: Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists. Best Pract Res Clin Rheumatol. 2010, 24: 683-692. 10.1016/j.berh.2010.06.002.CrossRef
15.
16.
go back to reference Dumoutier L, Louahed J, Renauld JC: Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000, 164: 1814-1819.CrossRef Dumoutier L, Louahed J, Renauld JC: Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000, 164: 1814-1819.CrossRef
17.
go back to reference Dumoutier L, Van Roost E, Colau D, Renauld JC: Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocytestimulating factor. Proc Natl Acad Sci USA. 2000, 97: 10144-10149.PubMedCentralCrossRef Dumoutier L, Van Roost E, Colau D, Renauld JC: Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocytestimulating factor. Proc Natl Acad Sci USA. 2000, 97: 10144-10149.PubMedCentralCrossRef
18.
go back to reference Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, Volk HD, Sterry W, Sabat R: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006, 36: 1309-1323. 10.1002/eji.200535503.CrossRef Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, Volk HD, Sterry W, Sabat R: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006, 36: 1309-1323. 10.1002/eji.200535503.CrossRef
19.
go back to reference Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005, 174: 3695-3702.CrossRef Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005, 174: 3695-3702.CrossRef
20.
go back to reference Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y: Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 2005, 52: 1037-1046. 10.1002/art.20965.CrossRef Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y: Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 2005, 52: 1037-1046. 10.1002/art.20965.CrossRef
21.
go back to reference Zenewicz LA, Flavell RA: Recent advances in IL-22 biology. Int Immunol. 2011, 23: 159-163. 10.1093/intimm/dxr001.CrossRef Zenewicz LA, Flavell RA: Recent advances in IL-22 biology. Int Immunol. 2011, 23: 159-163. 10.1093/intimm/dxr001.CrossRef
22.
go back to reference Kotenko SV, Langer JA: Full house: 12 receptors for 27 cytokines. Int Immunopharmacol. 2004, 4: 593-608. 10.1016/j.intimp.2004.01.003.CrossRef Kotenko SV, Langer JA: Full house: 12 receptors for 27 cytokines. Int Immunopharmacol. 2004, 4: 593-608. 10.1016/j.intimp.2004.01.003.CrossRef
23.
go back to reference Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004, 22: 929-979. 10.1146/annurev.immunol.22.012703.104622.CrossRef Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004, 22: 929-979. 10.1146/annurev.immunol.22.012703.104622.CrossRef
24.
go back to reference Renauld JC: Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol. 2003, 3: 667-676. 10.1038/nri1153.CrossRef Renauld JC: Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol. 2003, 3: 667-676. 10.1038/nri1153.CrossRef
25.
go back to reference Ren J, Feng Z, Lv Z, Chen X, Li J: Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α. J Rheumatol. 2011, 38: 2112-2118. 10.3899/jrheum.101377.CrossRef Ren J, Feng Z, Lv Z, Chen X, Li J: Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α. J Rheumatol. 2011, 38: 2112-2118. 10.3899/jrheum.101377.CrossRef
26.
go back to reference Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S: Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001, 276: 2725-2732. 10.1074/jbc.M007837200.CrossRef Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S: Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001, 276: 2725-2732. 10.1074/jbc.M007837200.CrossRef
27.
go back to reference Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity. 2004, 21: 241-254. 10.1016/j.immuni.2004.07.007.CrossRef Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity. 2004, 21: 241-254. 10.1016/j.immuni.2004.07.007.CrossRef
28.
go back to reference Meephansan J, Ruchusatsawat K, Sindhupak W, Thorner PS, Wongpiyabovorn J: Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol. 2011, 21: 501-504. Meephansan J, Ruchusatsawat K, Sindhupak W, Thorner PS, Wongpiyabovorn J: Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol. 2011, 21: 501-504.
29.
go back to reference Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, Matthys P: Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009, 60: 390-395. 10.1002/art.24220.CrossRef Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, Matthys P: Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009, 60: 390-395. 10.1002/art.24220.CrossRef
30.
go back to reference Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, Lunardi F, Calabrese F, Vezzù M, Dainese S, Molena B, Scanu A, Nardacchione R, Rubaltelli L, Dayer JM, Punzi L: Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther. 2010, 12: R148-10.1186/ar3090.PubMedCentralCrossRef Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, Lunardi F, Calabrese F, Vezzù M, Dainese S, Molena B, Scanu A, Nardacchione R, Rubaltelli L, Dayer JM, Punzi L: Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther. 2010, 12: R148-10.1186/ar3090.PubMedCentralCrossRef
31.
go back to reference Wright V, Moll JM: Psoriatic arthritis. Bull Rheum Dis. 1971, 21: 627-632. Wright V, Moll JM: Psoriatic arthritis. Bull Rheum Dis. 1971, 21: 627-632.
32.
go back to reference Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006, 54: 2665-2673. 10.1002/art.21972.CrossRef Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006, 54: 2665-2673. 10.1002/art.21972.CrossRef
33.
go back to reference Raychaudhuri SP, Raychaudhuri SK: The regulatory role of nerve growth factor and its receptor system in fibroblast-like synovial cells. Scand J Rheumatol. 2009, 38: 207-215. 10.1080/03009740802448866.CrossRef Raychaudhuri SP, Raychaudhuri SK: The regulatory role of nerve growth factor and its receptor system in fibroblast-like synovial cells. Scand J Rheumatol. 2009, 38: 207-215. 10.1080/03009740802448866.CrossRef
34.
go back to reference Raychaudhuri SK, Raychaudhuri SP: Functional significance of nerve growth factor and its receptor (TrkA) in inflammatory arthritis. Arthritis Res Ther. 2010, 12: 404-10.1186/ar3030.PubMedCentralCrossRef Raychaudhuri SK, Raychaudhuri SP: Functional significance of nerve growth factor and its receptor (TrkA) in inflammatory arthritis. Arthritis Res Ther. 2010, 12: 404-10.1186/ar3030.PubMedCentralCrossRef
35.
go back to reference Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A: Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007, 9: 461-417. 10.1007/s11926-007-0075-1.PubMedCentralCrossRef Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A: Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007, 9: 461-417. 10.1007/s11926-007-0075-1.PubMedCentralCrossRef
36.
go back to reference Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W: Interleukin-22, a T(H)17 cytokine, mediates IL-23 induced dermal inflammation and acanthosis. Nature. 2007, 445: 648-651. 10.1038/nature05505.CrossRef Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W: Interleukin-22, a T(H)17 cytokine, mediates IL-23 induced dermal inflammation and acanthosis. Nature. 2007, 445: 648-651. 10.1038/nature05505.CrossRef
37.
go back to reference Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, Park MK, Cho ML, Lee SH: IL-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2011, doi: 10.1002/art.33446 Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, Park MK, Cho ML, Lee SH: IL-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2011, doi: 10.1002/art.33446
38.
go back to reference Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P: Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009, 29: 210-214. 10.1007/s10875-008-9233-0.CrossRef Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P: Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009, 29: 210-214. 10.1007/s10875-008-9233-0.CrossRef
39.
go back to reference Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, Schaller M, Behrendt H, Ring J, Schmidt-Weber CB, Cavani A, Mempel M, Traidl-Hoffmann C, Eyerich K: IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with candida albicans. Eur J Immunol. 2011, 41: 1894-1901. 10.1002/eji.201041197.CrossRef Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, Schaller M, Behrendt H, Ring J, Schmidt-Weber CB, Cavani A, Mempel M, Traidl-Hoffmann C, Eyerich K: IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with candida albicans. Eur J Immunol. 2011, 41: 1894-1901. 10.1002/eji.201041197.CrossRef
40.
go back to reference Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, Guillet G, Bernard FX, Lecron JC, Morel F: Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL1{alpha}, and TNF-{alpha} Recapitulates Some Features of Psoriasis. J Immunol. 2010 Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, Guillet G, Bernard FX, Lecron JC, Morel F: Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL1{alpha}, and TNF-{alpha} Recapitulates Some Features of Psoriasis. J Immunol. 2010
41.
go back to reference Zhang Y, Dong J, He P, Li W, Zhang Q, Li N, Sun T: Genistein Inhibit Cytokines or Growth Factor-Induced Proliferation and Transformation Phenotype in Fibroblast-Like Synoviocytes of Rheumatoid Arthritis. Inflammation. 2012, 35: 377-387. 10.1007/s10753-011-9365-x.CrossRef Zhang Y, Dong J, He P, Li W, Zhang Q, Li N, Sun T: Genistein Inhibit Cytokines or Growth Factor-Induced Proliferation and Transformation Phenotype in Fibroblast-Like Synoviocytes of Rheumatoid Arthritis. Inflammation. 2012, 35: 377-387. 10.1007/s10753-011-9365-x.CrossRef
Metadata
Title
Functional role of IL-22 in psoriatic arthritis
Authors
Anupam Mitra
Smriti K Raychaudhuri
Siba P Raychaudhuri
Publication date
01-04-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3781

Other articles of this Issue 2/2012

Arthritis Research & Therapy 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.